Sun Pharma acquires 85% stake in JSC Biosintez

21 Dec 2016 Evaluate

Sun Pharmaceutical Industries has completed the acquisition of 85.1% stake in Russia-based JSC Biosintez. All necessary formalities for the closure of transaction have been concluded and the process of the acquisition has been completed on December 20, 2016. This acquisition is consistent with Sun Pharma's philosophy to invest in strategic emerging markets. This transaction gives the company access to local manufacturing capability across multiple dosage forms in Russia, enabling us to serve the Russia pharmaceutical market more effectively. Earlier, in November, the company’s wholly owned subsidiary entered into definitive agreements for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical firm, engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.

Sun Pharma Inds. Share Price

1804.95 -13.65 (-0.75%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×